Johnson & Johnson's third quarter earnings beat Wall Street's expectations, despite the mounting losses coming from thousands of lawsuits, according to CNBC.
In the third quarter of 2019, J&J reported revenue of $20.73 billion, beating the $20.07 billion analysts expected. In addition, the company's adjusted earnings per share hit $2.12 versus an expected $2.01.
J&J also raised its full-year guidance, expecting earnings between $8.62 to $8.67 per share and revenue in the range of $81.8 billion to $82.3 billion.
The strong third quarter as attributed to higher sales of cancer and other prescription drugs, according to CNBC.
In particular, the company's pharmaceutical business posted revenue of $10.88 billion, higher than the $10.41 billion expected. Its medical device unit reported $6.3 billion, better than the $6.27 expected.
J&J is currently facing thousands of lawsuits, ranging from claims that its talc-based baby powder causes cancer to allegations that it fueled the opioid crisis.
The company was ordered by an Oklahoma judge in August to pay $572 million for its part in the opioid crisis in that state and was ordered Oct. 9 by a Philadelphia jury to pay $8 billion in punitive damages for downplaying the risk its antipsychotic drug Risperdal could cause breast growth in boys.
J&J did not report its litigation expenses for the third quarter.
Read the full article here.
More articles on pharmacy:
Novant Health to open health clinics inside Walgreens
GlaxoSmithKline recalls prescription heartburn drug globally
BIO CEO to step down at the end of 2020
Novant Health to open health clinics inside Walgreens
GlaxoSmithKline recalls prescription heartburn drug globally
BIO CEO to step down at the end of 2020